STOCK TITAN

Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Voyager Therapeutics to participate in Fireside Chat at Canaccord Genuity Annual Growth Conference
Positive
  • Voyager Therapeutics' Chief Scientific Officer and Chief Financial Officer will participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023, at 10:30 a.m. ET
  • Investors can access the webcast of the presentation from Voyager's website
  • A replay of the webcast will be available on the Company's website for at least 30 days
Negative
  • None.

CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Scientific Officer Todd Carter, Ph.D., and Chief Financial Officer Peter Pfreundschuh will participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023, at 10:30 a.m. ET.

A webcast of the presentation may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcast will be archived on the Company's website for at least 30 days.

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Pfizer Inc., Novartis Pharma AG, Neurocrine Biosciences, Inc. and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.

Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. 

Contacts
Investors
Investors@vygr.com

Media
Peg Rusconi
prusconi@vergescientific.com


FAQ

When is Voyager Therapeutics participating in the Fireside Chat at Canaccord Genuity Annual Growth Conference?

Voyager Therapeutics is participating in the Fireside Chat on Thursday, August 10, 2023, at 10:30 a.m. ET

Where can investors access the webcast of the presentation?

Investors can access the webcast from Voyager's website

How long will the replay of the webcast be available?

The replay of the webcast will be available on the Company's website for at least 30 days

Voyager Therapeutics, Inc.

NASDAQ:VYGR

VYGR Rankings

VYGR Latest News

VYGR Stock Data

294.98M
45.35M
16.98%
65.4%
5.41%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
LEXINGTON